Sysmex (6869) · RiskFirst stated

Intellectual Property Infringement and Dispute Risks

First written in FY2024. . Latest entry: FY2024.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Complex risk involving IP infringement, counterfeit products and OSS complianceA theme 30 companies write about · 29 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2022: 1 of 11 companies on the "Worse" side.

10 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Showing 14 of the 30 companies compared. The sentences above are computed from all 30.

Full recordFilings, disclosures and news, newest first

FY2024First statedAnnual report
「If counterfeit products infringing the Group's intellectual property rights are distributed, the reliability of test results may not be ensured, potentially affecting medical institutions and patients. In addition, regardless of whether the Group has a valid defense, disputes over intellectual property rights may arise, including lawsuits alleging infringement of third-party intellectual property rights and demands for royalty payments.」
Organized as independent risks the impact of counterfeit products on test results, lawsuits alleging infringement of third-party intellectual property rights, and royalty demands. Also disclosed that trademark applications had been filed in 195 countries and regions and that the overseas holding ratio of intellectual property rights had reached 85%.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for Sysmex yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.